Lederer David J, Enright Paul L, Kawut Steven M, Hoffman Eric A, Hunninghake Gary, van Beek Edwin J R, Austin John H M, Jiang Rui, Lovasi Gina S, Barr R Graham
Department of Medicine, College of Physicians and Surgeons, Columbia University, New York, NY 10032, USA.
Am J Respir Crit Care Med. 2009 Sep 1;180(5):407-14. doi: 10.1164/rccm.200812-1966OC. Epub 2009 Jun 19.
Cigarette smoking is a risk factor for diffuse parenchymal lung disease. Risk factors for subclinical parenchymal lung disease have not been described.
To determine if cigarette smoking is associated with subclinical parenchymal lung disease, as measured by spirometric restriction and regions of high attenuation on computed tomography (CT) imaging.
We examined 2,563 adults without airflow obstruction or clinical cardiovascular disease in the Multi-Ethnic Study of Atherosclerosis, a population-based cohort sampled from six communities in the United States. Cumulative and current cigarette smoking were assessed by pack-years and urine cotinine, respectively. Spirometric restriction was defined as a forced vital capacity less than the lower limit of normal. High attenuation areas on the lung fields of cardiac CT scans were defined as regions having an attenuation between -600 and -250 Hounsfield units, reflecting ground-glass and reticular abnormalities. Generalized additive models were used to adjust for age, gender, race/ethnicity, smoking status, anthropometrics, center, and CT scan parameters.
The prevalence of spirometric restriction was 10.0% (95% confidence interval [CI], 8.9-11.2%) and increased relatively by 8% (95% CI, 3-12%) for each 10 cigarette pack-years in multivariate analysis. The median volume of high attenuation areas was 119 cm(3) (interquartile range, 100-143 cm(3)). The volume of high attenuation areas increased by 1.6 cm(3) (95% CI, 0.9-2.4 cm(3)) for each 10 cigarette pack-years in multivariate analysis.
Smoking may cause subclinical parenchymal lung disease detectable by spirometry and CT imaging, even among a generally healthy cohort.
吸烟是弥漫性实质性肺疾病的一个危险因素。亚临床实质性肺疾病的危险因素尚未有描述。
通过肺活量测定法受限情况以及计算机断层扫描(CT)成像上的高衰减区域来确定吸烟是否与亚临床实质性肺疾病相关。
我们在美国六个社区抽取的基于人群的队列研究——动脉粥样硬化多民族研究中,检查了2563名无气流阻塞或临床心血管疾病的成年人。分别通过吸烟包年数和尿可替宁评估累积吸烟量和当前吸烟情况。肺活量测定法受限定义为用力肺活量低于正常下限。心脏CT扫描肺野上的高衰减区域定义为衰减值在-600至-250亨氏单位之间的区域,反映磨玻璃样和网状异常。使用广义相加模型对年龄、性别、种族/民族、吸烟状况、人体测量学、中心和CT扫描参数进行校正。
肺活量测定法受限的患病率为10.0%(95%置信区间[CI],8.9-11.2%),在多变量分析中,每10个吸烟包年相对增加8%(95%CI,3-12%)。高衰减区域的中位数体积为119立方厘米(四分位间距,100-143立方厘米)。在多变量分析中,每10个吸烟包年,高衰减区域的体积增加1.6立方厘米(95%CI,0.9-2.4立方厘米)。
即使在一般健康的队列中,吸烟也可能导致通过肺活量测定法和CT成像可检测到的亚临床实质性肺疾病。